Most non-canonical proteins uniquely populate the proteome or immunopeptidome.
Combining RNA sequencing, ribosome profiling, and mass spectrometry, we elucidate the contribution of non-canonical translation to the proteome and major histocompatibility complex (MHC) class I immunopeptidome. Remarkably, of 14,498 proteins identified in three human B cell lymphomas, 2,503 are non-canonical proteins. Of these, 28% are novel isoforms and 72% are cryptic proteins encoded by ostensibly non-coding regions (60%) or frameshifted canonical genes (12%). Cryptic proteins are translated as efficiently as canonical proteins, have more predicted disordered residues and lower stability, and critically generate MHC-I peptides 5-fold more efficiently per translation event. Translating 5' "untranslated" regions hinders downstream translation of genes involved in transcription, translation, and antiviral responses. Novel protein isoforms show strong enrichment for signaling pathways deregulated in cancer. Only a small fraction of cryptic proteins detected in the proteome contribute to the MHC-I immunopeptidome, demonstrating the high preferential access of cryptic defective ribosomal products to the class I pathway.
['Ruiz Cuevas|Maria Virginia|MV|', 'Hardy|Marie-Pierre|MP|', 'Hollý|Jaroslav|J|', 'Bonneil|Éric|É|', 'Durette|Chantal|C|', 'Courcelles|Mathieu|M|', 'Lanoix|Joël|J|', 'Côté|Caroline|C|', 'Staudt|Louis M|LM|', 'Lemieux|Sébastien|S|', 'Thibault|Pierre|P|', 'Perreault|Claude|C|', 'Yewdell|Jonathan W|JW|']
ribosome profiling mass spectrometry non-canonical translation major histocompatibility complex peptides protein isoforms defective ribosomal products computational biology proteomic methods